Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis
The panel assessed doses of 3.39 mg/kg for small children and 1.31 mg/kg for adults
Tmax ~24-72 hours Half-Life: ~155 hours (6.5 days), enabling once-weekly dosing [2] Steady State: Achieved after approximately 4-5 weeks of weekly dosing Clearance: Primarily peptide degradation
RhoA/Rho-kinase in the cardiovascular system
(2005) Exenatide augments first- and second-phase insulin secretion (PubMed) Kolterman OG, et al
Glucagon-like peptide-1 (GLP-1) agonists belong to pharmacological use that helps to treat Type 2 Diabetes Mellitus (T2DM) and in some cases, support the weight loss journey among overweight adults
